Q2040 Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion

Short descriptor: Tisagenlecleucel car-pos t

⚠ Terminated HCPCS Level II 2026
Terminated Code
Q2040 was terminated as of 2018-12-31 and should not be reported for dates of service after that date. This page is retained for historical reference.
Open Q2040 in the app →

Look up Q2040 alongside ICD-10-CM diagnoses, the HCPCS Table of Drugs, and the AI coding assistant.

Q2040 is the HCPCS Level II code for Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion (2026). It belongs to Section Q — Temporary Codes. Under Medicare, its coverage status is: Carrier judgment. Part B pricing methodology: Drugs.

Classification & CMS Attributes

Medicare Coverage
Carrier judgment (code C)
Part B Pricing
Drugs (indicator 51)
Type of Service
Medical care
Effective Date
2019-01-01
Termination Date
2018-12-31
2026 Maintenance
No change this year

References

Cite This Page

Reference Q2040 with the canonical source and edition:

Q2040 — Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion. ICD-10 Coding Pro (HCPCS Level II 2026). https://icd10codingpro.com/hcpcs-codes/Q2040

Canonical URL: https://icd10codingpro.com/hcpcs-codes/Q2040

Related Codes in Section Q

Browse all HCPCS Level II sections →
Reviewed by Prajwal Shrestha, CPC, CRC
Certified Professional Coder (CPC) and Certified Risk Adjustment Coder (CRC) · AAPC Member ID 01997614 · About · Editorial policy · Content last reviewed: 2026-01-01

Get HCC Mappings, Clinical Summaries, and More

Access premium features including HCC risk adjustment, FDA drug indications, AI coding assistant, and comprehensive clinical context.

Start Free Trial